摘要
2021年11月英国药品和保健品管理局批准口服抗新型冠状病毒肺炎药物Molnupiravir用于治疗具有发展为中症和重症新型冠状病毒肺炎风险的轻、中度新型冠状病毒肺炎成人患者。Molnupiravir是全球首个获批上市的口服小分子新型冠状病毒肺炎特效药,是一种高效核糖核苷类似物的口服生物可利用形式。现对其药理作用、临床前研究、临床研究、安全性、局限性做一简单综述,以期为未来临床用药提供参考。
In November 2021,the Medicines and Healthcare Products Regulatory Agency(U.K.)approved oral anti-coronavirus disease 2019 drug-Molnupiravir to treat adult patients with mild to moderate coronavirus disease 2019 who are at risk of developing moderate and severe coronavirus disease 2019.Molnupiravir is the first oral small molecule coronavirus disease 2019 specific drug approved to market in the world,and it is a highly effective oral bioavailable form of ribonucleoside analogues.This paper briefly reviews its pharmacological effects,preclinical studies,clinical studies,safety and limitations,in order to provide references for future clinical drug use.
作者
刘依琳
霍记平
赵志刚
LIU Yi-lin;HUO Ji-ping;ZHAO Zhi-gang(Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2022年第20期2492-2496,共5页
The Chinese Journal of Clinical Pharmacology
关键词
新型冠状病毒
新型冠状病毒肺炎
口服抗新型冠状病毒肺炎药物
临床试验
severe acute respiratory syndrome coronavirus 2
coronavirus disease 2019
oral-anti-cornavirus disease 2019 drug
clinical trials
